Is ZTS a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Zoetis (ZTS) rests on Leader in a structurally growing market: Zoetis is the largest company in animal health, a market supported by the long-run humanization of pets, growing pet ownership, and rising global protein demand for livestock. Revenue (2026 guidance) is ~$9.7 billion to $10.0 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. Whether ZTS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). Spun out of Pfizer in 2013, it holds leading positions across dermatology, parasiticides, pain, vaccines, and other categories, with well-known franchises such as Apoquel and Cytopoint for pet itch and allergic skin conditions, the Simparica line of parasiticides, and Librela for osteoarthritis pain in dogs. Companion animal products, driven by the long-run humanization of pets and rising spending on their care, have become the larger and faster-growing part of the business, while livestock provides a more staple, protein-demand-linked base. Zoetis sells through veterinarians in the United States and internationally, invests heavily in research and development to sustain its innovation pipeline, and benefits from patents, brand loyalty, and deep vet relationships. Headquartered in Parsippany, New Jersey, it is widely viewed as a defensive-growth leader on the structural trend of people spending more on animal health, though it faces cyclical pet-visit softness, pricing pressure, and rising competition.
What's the case for buying ZTS?
1. Leader in a structurally growing market.
Zoetis is the largest company in animal health, a market supported by the long-run humanization of pets, growing pet ownership, and rising global protein demand for livestock. Owners increasingly treat pets as family and spend more on their care, giving Zoetis a durable, multi-year demand tailwind that is less tied to the economic cycle than many industries.
2. Innovation-driven franchises and pipeline.
Zoetis invests heavily in research and development and has built leading franchises in high-value categories, including dermatology (Apoquel, Cytopoint), parasiticides (the Simparica line), and monoclonal-antibody pain treatments such as Librela for dogs. A steady flow of new products and label expansions, backed by patents and vet relationships, helps sustain pricing power and growth.
3. Diversification and expanding adjacencies.
The business spans both companion animals and livestock, many species, and multiple product types (medicines, vaccines, diagnostics), which smooths results when any single category softens. Zoetis has also expanded into diagnostics and, through a planned acquisition of an animal-genomics business, aims to broaden its data and testing footprint alongside its therapeutics.
What are the risks to ZTS?
Zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. Competition is intensifying, including newer entrants and generics in key dermatology and parasiticide categories, and patent expirations can erode pricing over time. A large share of revenue comes from outside the United States, exposing it to currency swings and international regulatory and pricing risk. Livestock demand is tied to protein consumption, herd sizes, and disease outbreaks. As a premium-valued, high-quality name, the stock can carry an elevated multiple that leaves it vulnerable to de-rating if growth disappoints. It is a growth-oriented holding, not a deep-value or high-yield income stock.
How is ZTS valued? (as of Q1 2026 reported)
- Revenue (2026 guidance): ~$9.7 billion to $10.0 billion
- Q1 2026 revenue: ~$2.3 billion, up ~3% year over year
- Adjusted EPS (2026 guidance): ~$6.85 to $7.00
- Business mix: companion animal (larger, faster-growing) plus livestock
- Key franchises: Apoquel, Cytopoint, Simparica line, Librela, vaccines, diagnostics
- Geographic mix: United States plus large international segment
- Growth profile: mid-single-digit organic operational growth targeted for 2026
- Valuation style: premium multiple typical of a high-quality animal-health leader
Zoetis is valued as a high-quality, defensive-growth compounder, so it often trades at a premium price-to-earnings multiple relative to the broad market. In early 2026 it trimmed full-year guidance, citing softer pet-visit trends, price-sensitive pet owners, and competition, which pressured the stock. Livestock and international growth partly offset soft US companion-animal demand. Figures are approximate and change with each quarter and with currency movements; verify current numbers before relying on them.
How do you decide if ZTS is a buy?
Rather than asking whether ZTS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold ZTS indirectly through an index or sector ETF before adding more.
For the full picture, see the ZTS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about ZTS against your real portfolio and see your actual exposure before deciding.
The bottom line on ZTS
The bottom line: Zoetis's story right now is Leader in a structurally growing market, with revenue (2026 guidance) at ~$9.7 billion to $10.0 billion. If you believe that narrative continues, the call is about sizing ZTS sensibly and checking overlap with what you own; if you doubt it (the risk: zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on ZTS
- ZTS stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- ZTS stock forecast (the drivers and risks shaping the outlook)
- Does ZTS pay a dividend?
Build a basket around ZTS with Walnut
Use Zoetis as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is ZTS a good stock to buy right now?
+
The case for Zoetis right now is Leader in a structurally growing market, with revenue (2026 guidance) at ~$9.7 billion to $10.0 billion. If you believe that thesis holds, ZTS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Zoetis do?
+
Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs an
What are the main risks of ZTS?
+
Zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted trimmed guidance. Competition is intensifying, including newer entrants and generics in key dermatology and parasiticide categories, and patent expirations can erode pricing over time. A large share of revenue comes from outside the United States, exposing it to currency swings and international regulatory and pricing risk. Livestock demand is tied to protein consumption, herd sizes, and disease outbreaks. As a premium-valued, high-quality name, the stock can carry an elevated multiple that leaves it vulnerable to de-rating if growth disappoints. It is a growth-oriented holding, not a deep-value or high-yield income stock.
What is ZTS's ticker symbol?
+
ZTS, listed on the NYSE. Officially Zoetis Inc., headquartered in Parsippany, New Jersey. It trades during US market hours and is available at every major US brokerage as shares or fractional shares.
What does Zoetis do?
+
Zoetis is the world's largest animal health company. It develops and sells medicines, vaccines, diagnostics, and other products for companion animals like dogs and cats and for livestock such as cattle, swine, and poultry. Its portfolio includes leading dermatology, parasiticide, pain, and vaccine franchises sold primarily through veterinarians.
Who are Zoetis's main competitors?
+
By category. Animal-health drug rivals: Elanco, Merck Animal Health, Boehringer Ingelheim Animal Health, Ceva, and Virbac. Diagnostics: IDEXX Laboratories and other veterinary testing providers. Generics and alternatives also compete as patents expire. Zoetis stands out as the largest, most diversified pure-play leader in animal health.
Is Zoetis a defensive stock?
+
It is often described as defensive-growth. Demand for animal health, driven by pet humanization and livestock protein needs, tends to be more stable than the broader economy, and much of Zoetis's revenue is recurring. That said, it is not immune to softer veterinary visits, price sensitivity, and competition, so results and the stock can still fluctuate.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell ZTS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.